Germantown, MD, USA (August 20, 2012) – On July 20, 2012, bioLytical Laboratories received a CLIA waiver from the FDA for their INSTI HIV-1 Antibody Test, opening the door for a wider range of laboratory facilities to administer the test.

Amarex managed a pivotal clinical trial for bioLytical that demonstrated the necessary evidence needed to obtain the CLIA waiver.

Rick Galli, Chief Technical Officer at bioLytical, praised Amarex's work as integral to the application's success, "the statistical support [Amarex provided] proved to be invaluable and completely accurate in the final review by FDA. The cornerstone of this milestone achievement was the data from the clinical study, including the limit of detection study, and we came through all the review with solid outcome throughout."

The INSTI HIV-1 Antibody Test is a new, single use rapid test for the detection of antibodies to Human Immunodefinciency Virus Type 1 (HIV-1). The INSTI delivers results in 60 seconds, an improvement upon previously approved rapid HIV tests, which typically provide results in 10-20 minutes. Rapid HIV tests allow people to learn their HIV status in a single visit to a testing site, and allow for testing outside traditional laboratory settings. Consequently, rates of testing and diagnosis and care are improved.

The INSTI HIV-1 Antibody Test can be used in clinical laboratories, in public health laboratories and in point-of-care settings. The test is classified as Moderate Complexity under CLIA (Clinical Laboratory Improvements Amendments).

Amarex congratulates bioLytical Laboratories on their success, and looks forward to working together as the successful INSTI platform is applied to other diagnostic device developments in the future.

About Amarex Clinical Research

Amarex is a global, full service Contract Research Organization (CRO), whose leadership team has significant expertise conducting biomedical research, and whose combined experience includes the design and conduct of several hundred clinical research projects in many therapeutic indications. Amarex provides comprehensive services in Project Management (Phase I-IV, BE/BA, PK/PD), Regulatory Affairs, FDA Applications and Submissions, Applications and Submissions to international Health Authorities, GxP Compliance Audits, Clinical Operations, Adaptive Study Designs, Statistical Analysis, Data Management and General Consulting. Amarex has taken clients’ products through the entire approval process from writing the initial product approval strategy to the marketing approval application with a growing list of approved products. Amarex is committed to cost effective, high quality clinical product development.

Amarex Contact:
Patrick J. Burke
Business Development
patrickb@amarexcro.com
20201 Century Blvd., Fourth Floor
Germantown, MD 20874 USA
301 528 7000
www.amarexus.com